Fig. 2From: Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trialTornado diagram of one-way sensitivity analyses A when the charity assistance plan was not available; B when the charity assistance plan was available. PFS progression-free survival, PD progressed disease, ICER incremental cost-effectiveness ratioBack to article page